biosimilars

The Advancement of Biosimilars: A New Frontier in Medicine

In this recent CME offering from ClinicalSeriesLive, “The Advancement of Biosimilars: A New Frontier in Medicine, Clinical Applications and Concerns Regarding Biosimilar Products,” viewers gain valuable insight into the testing, approval, and use of biosimilars or treatment of various diseases. As of the production of the video, the only biosimilar...

leukemia

Treatment Options for Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia (CLL) is the most prevalent type of adult leukemia, with a median age of diagnosis of 72. However, 10 percent of patients are under age 50, twice as common in men as it is in women. There is a genetic predisposition; an environmental predisposition is uncertain, although...

Clinical Spotlight on Novel Treatments for Heart Failure

Editor’s note: This article on new treatment options for heart failure also applies to HCPs caring for patients living with diabetes. Our sister site, CardioCareLive.com, hosted this online CME session.  In the United States there are about 5.7 million people diagnosed with heart failure (HF), most of them female. With 870,000 new HF...

pediatric epilepsy

Pediatric Epilepsy: From early childhood through adolescence

In this CME offering from NeuroSeriesLive, Dr. Dennis Dlugos takes viewers through the current best practices for pediatric epilepsy. Using two case studies, Dr. Dlugos discusses diagnosis challenges and considerations, goals and concerns of medication treatments, and offers several non-medical treatment options. Dr. Dlugos, Professor of Neurology and Pediatrics at...

Diabetes Injectable Medications

2016 Screening Guidelines for Type 2 Diabetes

The ADA and AACE just jointly released 2016 screening guidelines for Type 2 Diabetes; they cast a significantly wider net. They now recommend screening everyone over the age of 45.  In addition, they are eliminating the term "diabetic" to describe a person living with diabetes.  Dr. Linda Girgis, MD, family practitioner, talks about...

CVD residual risk

Tackling CVD Residual Risk with Novel Therapies

Editor's note: This article on CVD Residual Risk addresses the HCP treatment and management of patients living with diabetes who have an increased risk for heart disease.  If you are interested in more information, check out our CME programs.  An expert cardiologist, takes an in-depth look at CVD residual risk....

melanoma CME

Melanoma: The Newest Immunotherapies and Target Drug Options

Melanoma accounts for less than two percent of all skin cancers but it is the cause of most skin cancer deaths. Just over 10,000 patients a year die from the disease. These sober statistics sparked a focus on new treatments to decrease mortality rates, such as BRAF and MEK inhibitors. ...

migraine treatment CME

Acute Migraine Treatment Choices

Migraine headaches are a debilitating collection of neurological symptoms often accompanied by one or more of the following: visual disturbances, nausea, vomiting, dizziness, extreme sensitivity to sound, light, touch, and smell, and tingling or numbness in the extremities or face. A common disorder, about 30 million people in America suffer...

MRSA

MRSA: Antimicrobial Advances of Gram-Positive Skin Infections

Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium which causes infections in different parts of the body. In the United States, MRSA accounts for an average of 59 percent of all emergency room admissions for patients with skin and soft tissue infections (SSTI). Although this percentage varies across the country, clearly...

World Cancer Day 2016

Our First CME World Cancer Day Challenge

  When did learning give back so much? From today through February 10th, join our World Cancer Day Challenge to earn CME and help us donate to cancer research at the same time! For every OMedLive session you attend, we'll donate $10 to the American Cancer Society. For every CME...

mycose

The War Against Invasive Mycoses: Keeping Patients Safe

When we take a look at the 10 most significant invasive fungal infections worldwide, over 2 million cases are reported each year, with a startlingly high average mortality rate of 45%. This war against invasive mycoses demands an urgent need for efficient diagnostic tests and safe and effective new drugs...

NSCLC lung cancer

Advanced NSCLC: Clinical Challenges for Personalized Treatment

According to the American Cancer Society, there were approximately 221,000 new cases of lung cancer in the U.S. in 2015. These patients accounted for about 13% of all new cancers. Of those, nearly 85-to-90 percent are non-small cell lung cancer (NSCLC). In this offering from OMedLive, Drs. Panos Fidias and...